Optune® device clinical trials

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This study looks at a new combination treatment for a type of brain cancer called glioblastoma. It combines a device called Optune, a chemotherapy drug called temozolomide, and a new drug called pembrolizumab, comparing it to Optune, temozolomide, and a dummy drug.